New MS treatment accepted by NICE

Eligible patients with multiple sclerosis (MS) must have the option to receive daclizumab (Zinbryta) on the NHS, NICE has ruled.

Daclizumab is recommended by NICE as an option for active relapsing–remitting MS. | SCIENCE PHOTO LIBRARY
Daclizumab is recommended by NICE as an option for active relapsing–remitting MS. | SCIENCE PHOTO LIBRARY

Daclizumab is recommended by NICE as an option for active relapsing–remitting MS in adults previously treated with disease-modifying therapy, and for rapidly evolving severe relapsing–remitting MS (defined as at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI), if alemtuzumab is contraindicated or otherwise unsuitable. 

Approval is contingent on the manufacturer continuing to provide the drug with the discount agreed in the patient access scheme.

NICE had previously daclizumab for NHS use in initial draft guidance published in September 2016.

Launched earlier this year, daclizumab is a humanised monoclonal antibody that binds to CD25 and modulates IL-2 signalling, decreasing the number of activated T-cells that contribute to the nerve injury seen in MS.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

intelog app

Access the full drug database and quick-reference tables on the go

Find out more